Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer - Ultra-HART
Jena University Hospital
150 participants
Apr 1, 2026
OBSERVATIONAL
Conditions
Summary
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.
Eligibility
Inclusion Criteria3
- no androgen deprivation therapy within the last 2 months prior to RT
- good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1)
- no secondary malignancy
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06355050